title: Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
abstract: Reduction of colony forming units by rifampicin-isoniazid therapy given 9-17 weeks post-infection was made more pronounced by immunotherapy with a vaccine made of fragmented Mycobacterium tuberculosis cells detoxified and liposomed (RUTI), given on weeks 17, 19 and 21 post-infection, in the murine model of tuberculosis in C57BL/6 and DBA/2 inbred strains. RUTI triggered a Th1/Th2 response, as demonstrated by the production of IgG1, IgG2a and IgG3 antibodies against a wide range of peptides. The histological analysis did not show neither eosinophilia nor necrosis, and granulomatous infiltration was only slightly increased in C57BL/6 mice when RUTI was administered intranasally.
authors.affiliation: Unitat de Tuberculosi Experimental, Department of Microbiology, Fundació Institut per a la Investigació en Ciències de la Salut "Germans Trias i Pujol", Universitat Autònoma de Barcelona, 08916 Badalona, Catalonia, Spain. pcardona@ns.hugtip.scs.es
authors.forename: Pere-Joan
authors.initials: PJ
authors.lastname: Cardona
authors.forename: Isabel
authors.initials: I
authors.lastname: Amat
authors.forename: Sergi
authors.initials: S
authors.lastname: Gordillo
authors.forename: Virginia
authors.initials: V
authors.lastname: Arcos
authors.forename: Evelyn
authors.initials: E
authors.lastname: Guirado
authors.forename: Jorge
authors.initials: J
authors.lastname: Díaz
authors.forename: Cristina
authors.initials: C
authors.lastname: Vilaplana
authors.forename: Gustavo
authors.initials: G
authors.lastname: Tapia
authors.forename: Vicenç
authors.initials: V
authors.lastname: Ausina
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000995:Antitubercular Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy; D007371:Interferon-gamma / Q000032:analysis; D007538:Isoniazid / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D012293:Rifampin / Q000627:therapeutic use*; D013154:Spleen / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy / Q000628:therapy*; D032581:Tuberculosis Vaccines / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000907:Antibodies, Bacterial; D000995:Antitubercular Agents; D007074:Immunoglobulin G; D032581:Tuberculosis Vaccines; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D007538:Isoniazid; D012293:Rifampin